Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

NASDAQ AKTX opened at $1.21 on Tuesday. The firm has a market cap of $71.81 million, a PE ratio of -2.37 and a beta of 1.34. Akari Therapeutics has a one year low of $1.05 and a one year high of $2.74. The stock’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.44.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKTX. Omnia Family Wealth LLC grew its position in Akari Therapeutics by 42.8% during the 4th quarter. Omnia Family Wealth LLC now owns 667,085 shares of the biopharmaceutical company’s stock worth $1,001,000 after acquiring an additional 200,000 shares during the last quarter. Wsfs Capital Management LLC bought a new stake in Akari Therapeutics during the 4th quarter worth approximately $150,000. Hikari Power Ltd grew its position in Akari Therapeutics by 45.7% during the 1st quarter. Hikari Power Ltd now owns 130,821 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 41,006 shares during the last quarter. Citadel Advisors LLC grew its position in Akari Therapeutics by 88.6% during the 2nd quarter. Citadel Advisors LLC now owns 52,265 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 24,553 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Akari Therapeutics during the 3rd quarter worth approximately $25,000. Institutional investors and hedge funds own 2.74% of the company’s stock.

About Akari Therapeutics (Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Further Reading

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.